Mydrane (Lidocaine Hydrochloride Monohydrate, Phenylephrine Hydrochloride, Tropicamide)

Lidocaine blocks voltage‑gated sodium channels in nerve membranes, producing local anesthesia. Phenylephrine stimulates alpha‑1 adrenergic receptors on the iris dilator muscle, causing contraction and pupil enlargement. Tropicamide antagonizes muscarinic receptors in the iris sphincter muscle, leading to relaxation and further dilation. Together they achieve both analgesia and mydriasis.

The specific volume and concentration of Mydrane are determined by the operating surgeon based on the procedure and patient characteristics. The prescribing ophthalmologist selects the appropriate intracameral dose at the time of surgery; no fixed public dosing regimen is provided.

Safety data for Mydrane in pregnant or lactating women are limited, and the product carries an unknown pregnancy category. Use during pregnancy or breastfeeding should only occur if the potential benefit justifies any potential risk, and it must be decided by the treating ophthalmologist in consultation with the patient.

To request Mydrane, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with separate administration of individual agents, Mydrane combines a local anesthetic (lidocaine) with two mydriatics (phenylephrine and tropicamide) in a single intracameral injection, reducing preparation time and potential dosing errors. Alternatives such as topical phenylephrine drops or separate intracameral lidocaine require multiple steps, whereas Mydrane offers a streamlined approach with comparable efficacy.

Mydrane should be stored at controlled room temperature, below 25 °C, in its original sealed container. Protect the solution from direct light, moisture, and extreme temperature fluctuations. Do not freeze the product, and inspect the vial for particulate matter before use.

Mydrane is injected directly into the anterior chamber of the eye (intracameral route) at the start of the surgical procedure. The surgeon introduces the prescribed volume through a sterile cannula, allowing immediate onset of anesthesia and pupil dilation. Proper aseptic technique and correct placement are essential for optimal effect.

Serious adverse events, although rare, can include severe allergic reactions such as anaphylaxis, marked intraocular pressure spikes, persistent mydriasis, corneal ulceration, endophthalmitis, and retinal detachment. Prompt recognition and management of these complications are critical, and patients should be monitored closely during and after surgery.

Mydrane is contraindicated in patients with known hypersensitivity to lidocaine, phenylephrine, tropicamide, or any excipients in the formulation. Caution is advised in individuals with uncontrolled glaucoma, severe cardiovascular disease, or those taking monoamine oxidase inhibitors, as excessive adrenergic stimulation may occur. The prescribing ophthalmologist must evaluate suitability before use.